Frontage, an Exton, Pa.-based CRO, has opened its newest facility in Secaucus, N.J., to expand its clinical research portfolio of services. The new 36,000-square-foot, state-of-the-art, 160-bed clinical research center was part of Frontage’s strategic growth plans to broaden clinical service capabilities and increase capacity.

The location of the new facility complements the existing center in nearby Hackensack. The Secaucus facility will include the ability to conduct a wider range of clinical studies including multiple concurrent studies and phase II-IV studies involving patient populations. This expansion will nearly triple the company’s clinical capacity in the U.S.

“We are excited to operate a second facility in New Jersey as it has been an ideal location for our clinical research due to the immediate access to the medical communities as well as subject and patient populations,” said Eileen McAuley, senior vice president of clinical services.

“Frontage’s ability to provide comprehensive support to our clients and their needs in the early drug development stage is greatly enhanced by our investment in facility expansion and clinical services infrastructure,” said Dr. Song Li, CEO of Frontage.